newsfilter
← Latest News
GlobeNewswire·

Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026

  • Arvinas, Inc. will review third quarter 2026 financial results & provide a corporate update during a live webcast on Tuesday, November 3, 2026 at 8:00 a.m. ET.
  • The webcast & replay will be accessible via the "Events and Presentations" section on the Arvinas investor website.
  • Arvinas is a clinical-stage biotechnology company developing PROTAC protein degrader therapies to remove disease-causing proteins.
  • Arvinas partnered with Pfizer to develop the first FDA-approved PROTAC, which is now outlicensed to Rigel Pharmaceuticals for global development, manufacturing, & commercialization.
  • Current investigational drug programs include ARV-393 (non-Hodgkin Lymphoma), ARV-102 (neurodegenerative disorders), ARV-027 (spinal-bulbar muscular atrophy), & ARV-6723 (advanced solid tumors).
  • Arvinas has advanced ARV-806 (KRAS G12D solid tumors) in the clinic & plans to seek an out-licensing agreement for future trials of this asset.
  • Arvinas is headquartered in New Haven, Connecticut.